Skip to main content

Table 2 Best overall response: phase II part

From: A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  Xe1000+Ev10+Ex25 (n = 70) Ev10+Ex25 (n = 70)
Best overall response
 CR 1 (1.4) 0
 PR 4 (5.7) 7 (10.0)
 Non-CR/non-PD, n (%) 10 (14.3) 8 (11.4)
  Non-CR/non-PD ≥ 24 weeks 4 (5.7) 3 (4.3)
 SD, n (%) 28 (40.0) 32 (45.7)
  SD ≥ 24 weeks 4 (5.7) 7 (10.0)
 PD, n (%) 16 (22.9) 14 (20.0)
 Not evaluable, n (%) 11 (15.7) 9 (12.9)
OR, n (%) 5 (7.1) 7 (10.0)
 Odds ratio (95% CI) [P value] 0.70 (0.20–2.32) [P = 0.5598]
 Median time to OR, months (range) 3.7 (1.8–5.3) 1.8 (1.6–7.2)
 Median duration of OR, months (95% CI) 5.6 (NC–NC) NC (1.8–NC)
Disease control, n (%) 13 (18.6) 17 (24.3)
 Odds ratio (95% CI) [P value] 0.70 (0.31–1.59) [P = 0.4008]
 Median duration of disease control, months (95% CI) NC (9.2–NC) 9.3 (9.0–NC)
  1. CI confidence interval, CR complete response, NC not calculable, OR objective response, PD progressive disease, PR partial response, SD stable disease
  2. Odds ratio and P value are obtained from logistic regression model adjusted for visceral involvement at screening. An odds ratio > 1 favours Xe1000+Ev10+Ex25
  3. Kaplan–Meier estimates